OCT 26, 2015 8:02 AM PDT

New Immunosuppressant Drug For Autoimmune Blood Diseases Undergoing Clinical Trials

WRITTEN BY: Kara Marker
Sirolimus, an immunosuppressant drug, as recently been used in clinical trials for patients with autoimmune blood disorders. Patients benefitting from sirolumus are highly resistant or intolerant to normal corticosteroid immunosuppressive therapy. Autoimmune lymphoproliferative syndrome (ALPS) is particularly responsive to experimental sirolimus treatments. This disease is extremely rare; only 200 ALPS patients have been identified worldwide (NIH). 

ALPS is a genetic disease that inhibits the body from producing the healthy amount of lymphoctes, resulting in a chronically swollen liver, spleen, and lymph nodes (NIH). ALPS and other autoimmune blood disorders can cause anemia, uncontrolled bleeding, and infection as the immune system targets healthy hematocytes (blood cells). 
A PET scan of an ALPS patient
Corticosteroids were discovered in the 1940s and are used often for regulating inflammation in autoimmune diseases. Unfortunately, their anti-inflammatory abilities are not without long-term adverse side effects. A 2011 review in Molecular and Cellular Endocrinology described corticosteroid treatment "clinical efficacy" as "compromised by the metabolic effects of long-treatment," including osteoporosis, hypertension, and type 2 diabetes. 

To bypass these unfavorable side effects as well as provide an option for ALPS patients resistant/intolerant to corticosteroids, scientists from the Children's Hospital of Philadelphia ran a clinical trial of 30 patients between 5 and 19 years old to see how sirolimus could be used to treat ALPS. 

Sirolimus has traditionally been prescribed to prevent the rejection of kidney transplants by suppressing the immune system (MedlinePlus). ALPS patients in the clinical trial received six months of sirolimus treatment, and there was large success with participants reaching normal blood cell counts. Patients also received a check-up after two years, and there were very few recorded adverse side effects. In addition, these patients were able to stop all other steroid treatments and rely on sirolimus to keep their disease in check. 

Senior study author David Teachey, MD, looks to sirolimus as a way for young ALPS patients to achieve "an improved quality of life as they continue treatment into adulthood."

In 2012, the Children's Hospital Boston also did a sirolumus clinical trail. Riley Cerabona, a child with CLOVES syndrome, participated in the trial. CLOVES (Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevus, Scoliosis) is very rare (ClovesSyndrome.org). Watch the video below to hear her story and more about the potential of sirolimus as an immunosuppressant. 



Source: EurekAlert

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 24, 2019
Immunology
SEP 24, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
NOV 17, 2019
Cell & Molecular Biology
NOV 17, 2019
Scientists Reveal a Link Between Brain Fog and Inflammation
When people get sick, they often also feel tired, which can be as troublesome as their disease....
NOV 27, 2019
Immunology
NOV 27, 2019
Playing "Tag" with the Immune System
Human cells employ an intricate tagging system to manage protein activity in the body. By “tagging” a protein with a certain modification, cell...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
FEB 10, 2020
Immunology
FEB 10, 2020
Measles infections can give the immune system amnesia
The immune system detects the presence of invading microbes that it recognizes from previous infections, and initiates a full-blown immune response. New re...
FEB 23, 2020
Immunology
FEB 23, 2020
New discovery could help preterm babies breathe easy
Babies born more than three weeks before full term are met with complicated and often life-threatening health challenges. Most notably, these tiny preterm...
Loading Comments...